Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in I… Read more
Deciphera Pharmaceuticals Inc - Asset Resilience Ratio
Deciphera Pharmaceuticals Inc (D05) has an Asset Resilience Ratio of 43.07% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Deciphera Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Deciphera Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €181.30 Million | 43.07% |
| Total Liquid Assets | €181.30 Million | 43.07% |
Asset Resilience Insights
- Very High Liquidity: Deciphera Pharmaceuticals Inc maintains exceptional liquid asset reserves at 43.07% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Deciphera Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Deciphera Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Deciphera Pharmaceuticals Inc (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Deciphera Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 47.03% | €222.71 Million | €473.57 Million | -10.18pp |
| 2022-12-31 | 57.21% | €259.75 Million | €454.04 Million | +10.97pp |
| 2021-12-31 | 46.23% | €198.57 Million | €429.48 Million | -18.52pp |
| 2020-12-31 | 64.76% | €416.03 Million | €642.43 Million | -9.03pp |
| 2019-12-31 | 73.79% | €459.26 Million | €622.41 Million | -- |